Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Brad Schenkel"'
Autor:
Neal Bhatia, Jayme Heim, J. Gabriel Vasquez, Tina Bhutani, Brad Schenkel, Ranga Gogineni, John Koo
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This report describes final primary results of a 64-week real-world study of the effect of tildrakizumab on
Externí odkaz:
https://doaj.org/article/0940ec5a269642b98555403e0ba78955
Autor:
Paul Karpecki, Victoria Barghout, Brad Schenkel, Lynn Huynh, Anamika Khanal, Brittany Mitchell, Mihran Yenikomshian, Enrico Zanardo, Cynthia Matossian
Publikováno v:
BMC Ophthalmology, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA®; OTX-1
Externí odkaz:
https://doaj.org/article/2b490c32997f4ec79ae629dd023b9db1
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of adults with moderate-to-severe plaque psoriasis. Little real-world evidence is available regarding the effects of tildrakizumab on patients’
Externí odkaz:
https://doaj.org/article/48d4a955160c43838e8c9c782436adba
Autor:
Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2378-2388 (2023)
Abstract Background Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting. Methods This retrospective observational study utilized
Externí odkaz:
https://doaj.org/article/af40e545f9924238b22b08dd911e1b09
Autor:
Steven R. Feldman, Susan D. Mathias, Brad Schenkel, Hilary H. Colwell, Kelly McQuarrie, Bruce Randazzo, Chenglong Han
Publikováno v:
Journal of Dermatology and Dermatologic Surgery, Vol 20, Iss 1, Pp 19-26 (2016)
Background: Patients with psoriasis (PsO) suffer from a variety of symptoms. Tools are needed to assess PsO symptoms and signs from the patient’s perspective. Objective: To develop a patient-reported outcome (PRO) measure to assess symptoms and sig
Externí odkaz:
https://doaj.org/article/630efae5bd8f4e09afdc20c7b2f9638b
Autor:
Wolfram Samlowski, Nicholas J. Robert, Liwei Chen, Brad Schenkel, Catherine Davis, Andriy Moshyk, Srividya Kotapati, Tayla Poretta, Jeffrey S. Weber
Publikováno v:
Cancer medicineREFERENCES.
Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real-world data on this regimen are limited in this setting.This retrospective observational study utilized data from the US Oncology Netwo
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s134
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s135
Autor:
Chenglong Han, Hilary H. Colwell, Kelly McQuarrie, Bruce Randazzo, Steven R. Feldman, Susan D. Mathias, Brad Schenkel
Publikováno v:
Journal of Dermatology and Dermatologic Surgery, Vol 20, Iss 1, Pp 19-26 (2016)
Background Patients with psoriasis (PsO) suffer from a variety of symptoms. Tools are needed to assess PsO symptoms and signs from the patient’s perspective. Objective To develop a patient-reported outcome (PRO) measure to assess symptoms and signs
Autor:
Esmond D. Nwokeji, Tayla Poretta, Nicholas J. Robert, Jeffrey S. Weber, Srividya Kotapati, Brad Schenkel, Bismark Baidoo, Andriy Moshyk, Wolfram E. Samlowski
Publikováno v:
Cancer Research. 80:1043-1043
Introduction: Nivolumab is approved for the adjuvant treatment of melanoma, and a 480 mg every 4 weeks (Q4W) flat-dosing monotherapy regimen was approved in the United States (March 2018). We examined real-world outcomes with different adjuvant nivol